Skip to main content
SpringerLink
Log in

Signal transduction inhibitors

  • Chapter
Drugs Affecting Growth of Tumours

Part of the book series: Milestones in Drug Therapy ((MDT))

  • 484 Accesses

Abstract

As a result of significant advances in fundamental research over the past 20 years, the process of signal transduction pathways involving receptor tyrosine kinases is now recognised to play a key role in the regulation of several physiological processes such as cell cycle,metabolism, growth, differentiation and proliferation. In addition, and more recently acknowledged, abnormal activation of these signal transduction pathways may lead to increased and uncontrolled cellular proliferation and a decrease in apoptosis, thus playing an important role in the development and growth of many human epithelial tumours.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Yarden Y, Sliwkowski M (2001) Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2: 127–137

    Article  PubMed  CAS  Google Scholar 

  2. Hackel P, Zwick E, Prenzel N, Ullrich A (1999) Epidermal growth factor receptors: critical mediators of multiple receptor pathways. Current Opin Cell Biol 11: 184–189

    Article  CAS  Google Scholar 

  3. Klapper L, Glathe S, Vaisman N, Hynes N, Andrews G, Sela M, Yarden Y (1999) The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors. Proc Natl Acad Sci USA 96: 4995–5000

    Article  PubMed  CAS  Google Scholar 

  4. Graus-Porta D, Beerli R, Daly J, Hynes N (1997) ErbB-2, the preferred heterodimerization partner for all erbB receptors, is a mediator of lateral signalling. EMBO J 16: 1647–1655

    Article  PubMed  CAS  Google Scholar 

  5. Olayoiye M, Neve R, Lane H, Hynes N (2000) The ErbB signalling network: receptor heterodimerization in development and cancer. EMBO J 19: 3159–3167

    Article  Google Scholar 

  6. Cobleigh M, Vogel C, Tripathy D, Robert N, Scholl S, Fehrenbacher L, Wolter J, Paton V, Shak S, Lieberman G et al. (1999) Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17: 2639–2648

    PubMed  CAS  Google Scholar 

  7. Vogel C, Cobleigh M, Tripathy D, Gutheil J, Harris L, Fehrenbacher L, Slamon D, Murphy M, Novotny W, Burchmore M et al. (2002) Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20: 719–726

    Article  PubMed  CAS  Google Scholar 

  8. Slamon D, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M et al. (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344: 783–792

    Article  PubMed  CAS  Google Scholar 

  9. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA et al. (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353: 1673–1684

    Article  PubMed  CAS  Google Scholar 

  10. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C et al.; Herceptin Adjuvant (HERA) Trial Study Team (2005) Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353: 1659–1672

    Article  PubMed  CAS  Google Scholar 

  11. Joensuu H, Kellokumpu-Lehtinen PL, Bono P, Alanko T, Kataja V, Asola R, Utriainen T, Kokko R, Hemminki A, Tarkkanen M et al.; FinHer Study Investigators (2006) Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 354: 789–790

    Article  Google Scholar 

  12. Saltz L, Kies M, Abbruzzese J, Azarnia N, Needle M (2003) The presence and intensity of the cetuximab-induced acne-like rash predicts increased survival in studies across multiple malignancies. Proc Amer Soc Clin Oncol 23: abstr 204

    Google Scholar 

  13. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C et al. (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 22: 337–345

    Article  Google Scholar 

  14. Bonner J, Harari P, Giralt J, Azarnia N, Cohen R, Raben D, Jones C, Kies M, Baselga J, Ang K (2004) Cetuximab prolongs survival in patients with locoregionally advanced squamous cell carcinoma of head and neck: A phase III study of high dose radiation therapy with or without cetuximab. Proc Amer Soc Clin Oncol 23: abstr 7022

    Google Scholar 

  15. Vanhoefer U, Tewes M, Rojo F, Dirsch O, Schleucher N, Rosen O, Tillner J, Kovar A, Braun AH, Trarbach T et al. (2004) Phase I study of the humanized antiepidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumours that express the epidermal growth factor receptor. J Clin Oncol 22: 175–184

    Article  PubMed  CAS  Google Scholar 

  16. Rowinsky E, Schwartz G, Gollob J, Thompson J, Vogelzang N, Figlin R, Bukowski R, Haas N, Lockbaum P, Li Y et al. (2004) Safety, Pharmacokinetics, and Activity of ABX-EGF, a Fully Human Anti-Epidermal Growth Factor Receptor Monoclonal Antibody in Patients With Metastatic Renal Cell Cancer. J Clin Oncol 22: 3003–3015

    Article  PubMed  CAS  Google Scholar 

  17. Giaccone G, Herbst R, Manegold C, Scagliotti G, Rosell R, Miller V, Natale R, Schiller J, Pawel J, Pluzanska A et al. (2004) Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: A Phase III trial — INTACT 1. J Clin Oncol 22: 777–784

    Article  PubMed  CAS  Google Scholar 

  18. Herbst R, Giaccone G, Schiller J, Natale R, Miller V, Manegold C, Scagliotti G, Rosell R, Oliff I, Reeves J et al. (2004) Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: A Phase III trial — INTACT 2. J Clin Oncol 22: 785–794

    Article  PubMed  CAS  Google Scholar 

  19. Lynch T, Bell D, Sordella R, Gurubhagavatula S, Okimoto R, Brannigan B, Harris P, Haserlat S, Supko J, Haluska F et al. (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 20: 2129–2139

    Article  Google Scholar 

  20. Paez J, Janne P, Lee J, Tracy S, Greulich H, Gabriel S, Herman P, Kaye F, Lindeman N, Boggon T et al. (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304: 1497–1500

    Article  PubMed  CAS  Google Scholar 

  21. Gatzemeier U, Pluzanska A, Szczesna A, Kaukel E, Roubec J, Brennscheidt U, De Rosa U, Mueller B, Von Pawel J (2004) Results of a phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced non-small cell lung cancer (NSCLC). Proc Amer Soc Clin Oncol 24: abstr 7010

    Google Scholar 

  22. Herbst R, Prager D, Hermann R, Miller V, Fehrenbacher L, Hoffman P, Johnson B, Sandler A, Mass R, Johnson D (2004) TRIBUTE — A phase III trial of erlotinib HCl (OSI-774) combined with carboplatin and paclitaxel (CP) chemotherapy in advanced non-small cell lung cancer (NSCLC). Proc Amer Soc Clin Oncol 24: abstr 7011

    Google Scholar 

  23. Shepherd F, Pereira J, Ciuleanu T, Tan E, Hirsh V, Thongprasert S, Bezjak A, Tu D, Santabárbara P, Seymour L (2004) A randomized placebo-controlled trial of erlotinib in patients with advanced non-small cell lung cancer (NSCLC) following failure of 1st line or 2nd line chemotherapy. A National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial. Proc Amer Soc Clin Oncol 24: abstr 7022

    Google Scholar 

  24. Van Oosterom A, Judson I, Verweij J, Stroobants S, Donato di Paola E, Dimitrijevic S, Martens M, Webb A, Sciot R, Van Glabbeke M et al. (2001) Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet 358: 1421–1423

    Article  PubMed  Google Scholar 

  25. Demetri G, von Mehren M, Blanke C, Van den Abbeele C, Eisenberg S, Roberts P, Heinrich M, Tuveson D, Singer S, Janicek M et al. (2002) Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumours. N Engl J Med 347: 472–480

    Article  PubMed  CAS  Google Scholar 

  26. O’Brien S, Guilhot F, Larson R, Gathmann I, Baccarani M, Cervantes F, Cornelissen J, Fischer T, Hochhaus A, Hughes T et al. (2003) Imatinib compared to interfron and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukaemia. N Engl J Med 348: 994–1004

    Article  PubMed  CAS  Google Scholar 

  27. Peggs K, Mackinnon S (2003) Imatinib mesylate — the new gold standard for treatment of chronic myeloid leukaemia. N Engl J Med 348: 1048–1050

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical Oncology, Erasmus University Medical Center Rotterdam, PO Box 2040, 3000 CA, Rotterdam, The Netherlands

    Ferry A. L. M Eskens

Authors
  1. Ferry A. L. M Eskens
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Medical Oncology, VU Medical Center, De Bolelaan 1117, 1081 HV, Amsterdam, The Netherlands

    Herbert M. Pinedo  & Carolien H. Smorenburg  & 

Rights and permissions

Reprints and permissions

Copyright information

© 2006 Birkhäuser Verlag/Switzerland

About this chapter

Cite this chapter

Eskens, F.A.L.M. (2006). Signal transduction inhibitors. In: Pinedo, H.M., Smorenburg, C.H. (eds) Drugs Affecting Growth of Tumours. Milestones in Drug Therapy. Birkhäuser Basel. https://doi.org/10.1007/3-7643-7407-1_8

Download citation

Publish with us

Policies and ethics

Search

Navigation